Search results for "Dose"

showing 10 items of 2247 documents

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Progestogens stimulate prostacyclin production by human endothelial cells.

2005

BACKGROUND: The effects of progestogens on endothelial physiology are poorly studied. Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase (COX) in endothelium. We examined the effects of two clinically used progestogens, progesterone and medroxyprogesterone acetate (MPA), on prostacyclin production by cultured human umbilical vein endothelial cells (HUVEC) and the possible role of progesterone receptors and both COX enzymes. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or MPA and prostacyclin production was measured in culture medium. RESULTS: Both progestogens significantly increased prostacyclin release in a time- and dose-dependent man…

medicine.medical_specialtyUmbilical VeinsEndotheliumProstacyclinMedroxyprogesterone AcetateUmbilical veinInternal medicineProgesterone receptormedicineMedroxyprogesterone acetateHumansCyclooxygenase InhibitorsReceptorCells CulturedNitrobenzenesProgesteroneSulfonamidesbiologyCyclooxygenase 2 InhibitorsDose-Response Relationship DrugEstradiolRehabilitationObstetrics and GynecologyEndothelial CellsMembrane ProteinsEpoprostenolEndothelial stem cellMifepristoneEndocrinologymedicine.anatomical_structureReproductive MedicineCyclooxygenase 2Prostaglandin-Endoperoxide Synthasescardiovascular systembiology.proteinCyclooxygenase 1PyrazolesCyclooxygenaseEndothelium VascularProgestinsReceptors Progesteronemedicine.drugHuman reproduction (Oxford, England)
researchProduct

Is GH dosing optimal in female patients with adult-onset GH deficiency? An analysis from the NordiNet® International Outcome Study

2017

SummaryObjective To evaluate gender differences in GH dosing, IGF-I and cardiovascular risk markers in adults with GH deficiency (GHD). Design NordiNet® International Outcome Study (NCT00960128), a noninterventional, multicentre study, evaluates the long-term effectiveness and safety of Norditropin® (Novo Nordisk A/S) in the real-life clinical setting. Patients Nondiabetic patients (n = 252; 41·7% female) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH therapy and glycosylated haemoglobin (HbA1c) data at baseline and 4 years. Measurements Effects of gender (adjusted for baseline age and body mass index [BMI], average GH dose, treatment duration and concomitant medication) on …

medicine.medical_specialtyWaistmedicine.diagnostic_testbusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematology03 medical and health sciencesDose–response relationship0302 clinical medicineEndocrinologyEndocrinologyInternal medicineConcomitantmedicineDosingYoung adultbusinessLipid profileBody mass indexGH DeficiencyClinical Endocrinology
researchProduct

Past and present work practices of European interventional cardiologists in the context of radiation protection of the eye lens—results of the EURALO…

2018

International audience; This paper investigates over five decades of work practices in interventional cardiology, with an emphasis on radiation protection. The analysis is based on data from more than 400 cardiologists from various European countries recruited for a EURALOC study and collected in the period from 2014 to 2016. Information on the types of procedures performed and their annual mean number, fluoroscopy time, access site choice, x-ray units and radiation protection means used was collected using an occupational questionnaire. Based on the specific European data, changes in each parameter have been analysed over decades, while country-specific data analysis has allowed us to dete…

medicine.medical_specialty[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyRadiology InterventionalTotal occlusion030218 nuclear medicine & medical imaging03 medical and health sciencesDose limit0302 clinical medicineCardiologistsRadiation Protectionaccess routesAccess routesCardiac proceduresLens CrystallineMedicineFluoroscopyHumansMedical physicsEye lensWaste Management and Disposalmedicine.diagnostic_testInterventional cardiologybusiness.industryinterventional cardiologyPublic Health Environmental and Occupational HealthHemodynamicsWorkloadGeneral Medicine3. Good healthfluoroscopywork practice of interventional cardiologistsEuropeFluoroscopyWork practice of interventional cardiologistsRadiation protectionbusinessElectrophysiologic Techniques Cardiacradiation protection
researchProduct

Vitellogenesis inhibition in Oncopeltus fasciatus females (Heteroptera: Lygaeidae) exposed to cadmium

2005

Abstract Newly moulted females of the insect Oncopeltus fasciatus were exposed to cadmium (Cd) dissolved in the drinking water (50–400 mg l −1 Cd) for 5 days. Cd exposure delayed ovarian maturation and inhibited egg production. Exposure to Cd, moreover, decreased hemolymph levels of the two major vitellogenin polypeptides of O. fasciatus , VG1 and VG2, in a concentration-dependent way, probably by a reduction in their synthesis. The ovarian levels of VG1 and VG2 were also decreased in Cd-exposed females. It was next investigated whether Cd effects might be a consequence of the endocrine disruption of vitellogenin synthesis, which is controlled by juvenile hormone (JH). JH replacement therap…

medicine.medical_specialtyanimal structuresPhysiologyFat Bodychemistry.chemical_elementHeteropteraVitellogeninsVitellogeninHemolymphInternal medicineHemolymphmedicineAnimalsEndocrine systemReceptorCadmiumDose-Response Relationship DrugbiologyReproductionOvaryVitellogenesisFeeding BehaviorJuvenile HormonesEndocrinologychemistryInsect ScienceJuvenile hormonebiology.proteinFemaleVitellogenesisFood DeprivationVitellogeninsCadmiumJournal of Insect Physiology
researchProduct

The toxic and lethal effects of the trehalase inhibitor trehazolin in locusts are caused by hypoglycaemia

2003

SUMMARY The main blood sugar of locusts is trehalose, which is hydrolysed to two glucose units by trehalase. Homogenates of locust flight muscles are rich in trehalase activity, which is bound to membranes. A minor fraction of trehalase is in an overt form while the remainder is latent, i.e. active only after impairing membrane integrity. Trehazolin, an antibiotic pseudosaccharide,inhibits locust flight muscle trehalase with apparent Ki-and EC50 values of 10–8 mol l–1and 10–7 mol l–1, respectively. Trehazolin is insecticidal: 50 μg injected into locusts completely and selectively blocked the overt form of muscle trehalase (with little effect on latent activity) and killed 50% of the insects…

medicine.medical_specialtyanimal structuresPhysiologyTrehalase activityBlood sugarGrasshoppersIn Vitro TechniquesAquatic ScienceBiologyCarbohydrate metabolismDisaccharideschemistry.chemical_compoundInternal medicineHemolymphmedicineAnimalsTrehalaseTrehalaseMolecular BiologyEcology Evolution Behavior and SystematicsLethal dosebiology.organism_classificationTrehaloseGlucoseEndocrinologyBiochemistrychemistryFlight AnimalInsect ScienceAnimal Science and ZoologyLocustJournal of Experimental Biology
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.

2009

Abstract Abstract 1290 Poster Board I-312 Background Excessive bleeding represents a major complication of surgical interventions, and its control is especially relevant in patients with Congenital Bleeding Disorders. In FVII deficiency, scanty data is available in surgery to guide treatment strategies. Methods The STER (Seven Treatment Evaluation Registry) is a multi-centre, prospective, observational, web-based registry providing the frame for an extensive and structured data collection. Results As of Dec. 2008, sixty-three surgical operations (36 “major” and 27 “minor”) were performed in 54 subjects (29 females and 25 males) with a FVII deficiency (31 previously symptomatic; 9 with FVIIc…

medicine.medical_specialtybiologyDosebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryThrombosisEffective dose (pharmacology)SurgerySettore MED/15 - Malattie Del SangueDental extractionRecombinant factor VIIaHemostasisOrthopedic surgerymedicinebiology.proteinfactor VIIbusinessGynecological surgery
researchProduct

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and …

2019

Introduction: The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint is the achievement of bone marrow minimal residual disease (MRD) negativity. However, other methods of disease evaluation in serum such as heavy+light chain (HLC) assessment, with a potential complementary value to the IMWG response criteria, have also been tested. Aim: To evaluate the performance of HLC assay in HRsMM pts at diagnosis and after consolidation, comparing the results with standard serological methods and Next Generation Flow (NGF) for the assessment of bone marrow MRD. Patients and Methods: Ninety HRsMM pts include…

medicine.medical_specialtybusiness.industryImmunologyHigh dose melphalanNegativity effectCell BiologyHematologyStandard methodsmedicine.diseaseBiochemistryMinimal residual diseaseResponse assessmentAssessment dataFamily medicineClinical valueMedicinebusinessMultiple myelomaBlood
researchProduct